Sun Pharmaceutical Industries Limited

Quick facts

Marketed products

• Bromday™
• Halobetasol Topical Lotion · Dermatology
  Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.
• Injections of tildrakizumab · Immunology/Dermatology
  Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.
• SAPHRIS · Psychiatry
  SAPHRIS (asenapine) is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.
• TILD · Immunology
  Tild is a small molecule that works by interacting with a specific target in the body.

Phase 3 pipeline

• Brinzolamide ophthalmic suspension · Ophthalmology
  Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.
• ISV-303 · Oncology
  ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.
• ISV-305 · Oncology
  ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.
• matching placebo injections
  Matching placebo injections are used to compare the efficacy of a new drug to a placebo.
• OTX-101 0.09% · Ophthalmology
  OTX-101 is a topical ophthalmic solution used to treat dry eye disease.
• PART 1: Double-blind Placebo-controlled · Psychiatry
  This drug is a selective serotonin reuptake inhibitor.
• SPIL1033 · Diabetes
  SPIL1033 is a small molecule drug that targets the SGLT2 receptor.
• vehicle of OTX-101
• Zero-dose · Infectious Diseases
  Zero-dose is a vaccine candidate that uses a novel approach to stimulate an immune response without the need for a traditional vaccine dose.

Phase 2 pipeline

• abiraterone acetate with Methylprednisolone
• GL0034 Dose Level 1
• GL0034 Dose Level 2
• GL0034 Dose Level 3
• GL0034 Dose Level 4
• GL0034 Dose Level 5
• GL0034 Dose Level 6
• MM-II dose I
• MM-II dose II
• MM-II dose III
• OTX-101 0.05%
• Pregnant women exposed to tildrakizumab
• SCD-044_Dose 1
• SCD-044_Dose 2
• SCD-044_Dose 3
• SUNPG1623 I
• SUNPG1623 II
• SUNPG1623 III
• SUNPG1623 IV

Phase 1 pipeline

• GL0034

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Sun Pharmaceutical Industries Limited portfolio CI brief
• Sun Pharmaceutical Industries Limited pipeline updates RSS